JNJ

AI Research

Oncology pipeline FDA approvals + Citi raises PT to $274

Johnson & Johnson is enhancing its oncology and MedTech presence through new FDA approvals while 2025 revenue rose 6% to $94.19 billion, with net income surging 90.6% to $26.80 billion. Citi raised its price target to $274 and Bank of America raised its target to $227, reflecting confidence in J&J's growth outlook despite ongoing litigation risks. The stock trades at $241.65, slightly above the average analyst 12-month target of $229.89, suggesting limited near-term upside by consensus estimates.